vaccin
protect
sever
import
infecti
diseas
mani
other
still
lack
effect
vaccin
abil
virus
rapidli
mutat
alter
antigen
makeup
eg
influenza
hiv
well
potenti
interfer
differ
viru
serotyp
eg
dengu
viru
made
vaccin
develop
challeng
task
given
infect
virus
result
signific
number
case
high
mortal
rate
rapid
develop
potent
therapeut
measur
potenti
save
live
limit
magnitud
outbreak
technolog
advanc
field
immunoglobulin
g
igg
research
gener
good
safeti
profil
observ
antibodybas
therapi
therapeut
antibodi
becom
attract
candid
treat
infecti
diseas
recent
ebola
outbreak
west
africa
good
exampl
potenti
mab
cocktail
antiinfect
strategi
exampl
includ
use
mab
hendra
viru
palivizumab
target
respiratori
syncyti
viru
rsv
result
signific
reduct
incid
hospit
given
need
new
antivir
therapi
consider
advanc
igg
research
grow
interest
develop
therapeut
antibodi
infecti
diseas
bind
affin
antibodi
virus
directli
impact
efficaci
mab
suggest
targetspecif
mechan
like
account
much
efficaci
therapeut
mab
howev
mani
studi
also
highlight
contribut
fcmediat
immun
effector
function
modul
efficaci
mab
antigenpres
cell
dendrit
cell
monocyt
macrophag
intern
antibodyopson
virus
via
fcreceptormedi
phagocytosi
result
antigen
process
present
effector
cell
adapt
immun
system
eventu
lead
viru
clearanc
hand
neutrophil
monocyt
macrophag
mast
cell
natur
killer
nk
cell
kill
infect
cell
opson
antibodi
process
describ
antibodydepend
cellmedi
cytotox
adcc
immun
complex
expect
phagocytos
fcreceptor
bear
cell
clear
blood
circul
deliv
virus
monocyt
macrophag
subneutr
antibodi
level
result
antibodyenhanc
infect
due
abil
serv
host
viral
replic
support
theori
subneutr
level
antibodi
shown
result
increas
infect
virus
dengu
viru
denv
ross
river
viru
influenza
viru
ebv
henc
therapeut
antibodi
ought
deliv
dose
high
enough
prevent
antibodyenhanc
viru
infect
avoid
cytokin
storm
result
excess
stimul
fcgamma
receptor
given
delic
balanc
antibodi
efficaci
advers
side
effect
need
develop
method
better
assess
fcmediat
effector
function
trigger
therapeut
antibodi
could
benefici
futur
develop
antibodi
engin
possess
enhanc
therapeut
activ
review
signific
variou
aspect
fcmediat
effector
function
involv
viru
neutral
factor
potenti
affect
engag
improv
understand
process
would
allow
identif
predict
factor
better
assess
efficaci
therapeut
antibodi
facilit
develop
engin
therapeut
antibodi
improv
efficaci
among
differ
class
immunoglobulin
iga
igd
ige
igg
igm
igg
commonli
use
henc
focu
review
gener
antibodi
consist
two
distinct
function
unit
fab
fc
region
figur
fab
portion
antibodi
contain
variabl
region
compris
three
hypervari
complementaritydetermin
region
bind
specif
antigen
epitop
bind
affin
fab
virus
determin
bind
assay
elisa
special
precis
method
biacor
surfac
plasmon
reson
fab
bind
virus
block
receptor
interact
host
therebi
hinder
attach
subsequ
viru
entri
addit
sever
studi
suggest
antibodi
target
region
receptorbind
site
also
neutral
instanc
antibodi
bind
fusogen
transmembran
protein
inhibit
viruscel
bind
abl
neutral
infect
recogn
fusionintermedi
form
postattach
step
similarli
neutral
antibodi
bind
west
nile
viru
denv
shown
block
infect
postattach
step
altogeth
investig
suggest
fab
portion
neutral
antibodi
function
either
block
viru
attach
inhibit
viru
fusion
contrast
fc
portion
antibodi
bind
immun
cell
mononuclear
phagocyt
system
monocyt
macrophag
dendrit
cell
shown
import
modul
efficaci
therapeut
mab
due
involv
phagocytosi
cytokin
product
adcc
complementdepend
cytotox
cdc
aid
viru
neutral
figur
howev
whether
fc
effector
function
activ
inhibit
depend
subtyp
engag
among
humanactiv
highest
affin
monomer
igg
immun
complex
hand
bind
strongli
immun
complex
monomer
igg
requir
accessori
immunoreceptor
tyrosinebas
activ
motif
itam
bear
gammachain
signal
transduct
contrast
itam
motif
locat
within
cytoplasm
tail
figur
activ
cluster
srcrelat
tyrosin
kinas
eg
src
fyn
fgr
hck
lyn
activ
phosphoryl
result
itam
phosphoryl
mediat
recruit
activ
protein
kinas
spleen
tyrosin
kinas
syk
famili
kinas
activ
kinas
catalyz
activ
downstream
kinas
initi
signal
cascad
sever
pathway
trigger
immun
effector
function
hand
cluster
inhibitori
receptor
activ
result
phosphoryl
immunoreceptor
tyrosinebas
inhibitori
motif
itim
recruit
activ
phosphatas
src
homolog
domaincontain
inositol
phosphatas
tyrosin
phosphatas
phosphatas
dephosphoryl
kinas
downstream
itammedi
signal
transduct
inhibit
activ
signal
figur
thu
colig
inhibitori
activ
result
abrog
itammedi
immun
effector
function
interact
activ
antibodi
directli
affect
efficaci
therapeut
antibodi
instanc
efficaci
clinic
approv
anticanc
mab
rituximab
mab
trastuzumab
human
mab
significantli
reduc
mice
defici
activ
compar
wildtyp
mice
contrast
mice
defici
inhibitori
increas
antibodymedi
cytolyt
activ
observ
addit
common
singlenucleotid
polymorph
gene
posit
gene
posit
lead
signific
reduct
bind
igg
respons
clinic
approv
mab
trastuzumab
rituximab
cetuximab
antiegf
mab
furthermor
fc
modif
use
f
ab
alter
interact
fc
directli
affect
fceffector
function
henc
therapeut
outcom
exampl
hiatt
et
al
demonstr
differ
glycan
variant
palivizumab
mediat
differ
level
adcc
affect
vivo
efficaci
palivizumab
rsv
overal
studi
suggest
therapeut
mab
direct
similar
antigen
target
may
differ
clinic
profil
depend
interact
neonat
fc
receptor
fcrn
structur
distinct
fcreceptor
express
variou
cell
type
eg
vascular
endothelium
cell
monocyt
macrophag
fcrn
bind
igg
within
acid
environ
endocyt
vacuol
physiolog
ph
immun
complex
bind
fcrn
sort
antigenprocess
endosom
recycl
endosom
howev
monomer
igg
sort
recycl
endosom
recycl
igg
back
cell
surfac
follow
endocytosi
thu
prevent
intracellular
degrad
igg
allow
antibodi
immun
complex
persist
blood
circul
sever
week
treatment
mutat
posit
significantli
increas
bind
fcrn
halflif
antibodi
without
affect
antigenbind
fcmediat
effector
function
improv
affin
fcrn
extend
halflif
antibodi
never
link
increas
clinic
efficaci
howev
vivo
studi
knockout
mous
model
suggest
antitumor
activ
bevacizumab
antivegf
cetuximab
antiegf
significantli
improv
bind
fcrn
increas
furthermor
recent
studi
shown
administr
broadli
neutral
antibodi
enhanc
fcrn
affin
improv
protect
infect
nonhuman
primat
increas
serum
halflif
also
enhanc
transcytosi
antibodi
mucos
surfac
slower
clearanc
antibodi
improv
protect
less
frequent
dose
schedul
would
expect
potenti
reduc
complianc
issu
moreov
extend
halflif
would
ensur
level
circul
antibodi
kept
suffici
high
viru
neutral
would
also
minim
risk
antibodydepend
enhanc
ade
viru
infect
would
particularli
use
virus
denv
ade
hypothes
result
increas
viremia
increas
risk
sever
dengu
howev
effect
improv
halflif
antibodi
test
avoid
potenti
toxic
advers
effect
given
import
mediat
viru
neutral
fc
effector
function
better
understand
therapeut
antibodi
neutral
viru
infect
cell
impact
implement
dose
regiment
allow
develop
improv
therapeut
antibodi
infecti
diseas
discuss
approach
use
test
variou
fcmediat
effector
function
describ
process
could
contribut
effici
neutral
virus
phagocytosi
play
critic
role
clear
iggopson
pathogen
system
circul
augment
antigen
present
crosslink
phagocyt
initi
downstream
signal
result
phosphoryl
activ
kinas
phosphatidyl
inositol
kinas
akt
directli
involv
reorgan
actin
cytoskeleton
membran
remodel
antibodyopson
virus
direct
lysosom
antigen
process
peptid
human
monocyt
shown
involv
neutral
viru
immun
complex
instanc
reduct
antibodyopson
infect
monocytederiv
macrophag
observ
upon
inhibit
reduc
express
use
small
interf
rna
also
result
reduc
antibodi
requir
denv
neutral
monocyt
reinforc
role
denv
neutral
exact
mechan
involv
remain
fulli
elucid
activ
demonstr
induc
express
proinflammatori
mediat
associ
traffick
immun
complex
directli
target
viru
immun
complex
late
endosom
lysosom
enhanc
antigen
process
antigen
present
tcell
occur
earli
min
crosslink
contrast
crosslink
result
slower
traffick
immun
complex
traffick
late
endosom
lysosom
compart
observ
time
interv
late
endosom
lysosom
viral
protein
degrad
peptid
fragment
bind
mhc
class
ii
molecul
present
plasma
membran
tcell
activ
besid
respons
immun
complex
also
shown
increas
respons
immun
complex
shuttl
antigenprocess
endosom
stimul
mhc
class
crosspresent
machineri
present
precis
activ
involv
mhc
class
crosspresent
still
remain
specul
besid
neutral
antigenprocess
endosom
antibodyopson
virus
intern
cell
may
also
bind
tripartit
motifcontain
protein
cytosol
igg
receptor
target
antibodyopson
virus
proteasom
degrad
via
ubiquitin
ligas
activ
interest
mode
neutral
shown
particularli
effect
nonenvelop
virus
adenoviru
signific
antigenpresent
presenc
antigen
uptak
also
demonstr
vivo
protect
mediat
antibodi
elimin
mice
dendrit
cell
depriv
microglobulin
transport
associ
antigen
process
tap
mhcii
howev
iggmedi
uptak
virus
alway
favor
host
monocyt
macrophag
import
site
replic
virus
denv
ross
river
viru
influenza
viru
ebv
increas
intern
antibodyopson
virus
via
may
therefor
result
enhanc
infect
antibodi
present
suffici
level
requir
viru
neutral
occur
via
extrins
intrins
ade
extrins
ade
immun
complex
form
virus
subneutr
level
antibodi
lead
increas
number
infect
cell
due
increas
uptak
phagocytosi
besid
increas
uptak
signal
also
increas
product
antiinflammatori
cytokin
act
via
suppressor
cytokin
signal
system
suppress
innat
immun
result
increas
viru
replic
output
infect
cell
addit
virus
also
directli
ligat
inhibitori
receptor
suppress
innat
immun
instanc
recent
demonstr
antibodyopson
dengu
colig
inhibitori
receptor
leukocyt
immunoglobulinlik
receptor
subfamili
b
member
activ
phosphatas
inhibit
activ
signal
transduc
activ
transcript
subsequ
interferonstimul
gene
isg
express
also
shown
interact
viral
antigen
human
cytomegaloviru
glycoprotein
although
mediat
ade
viru
infect
appear
effect
henc
pathogen
replic
effici
monocyt
macrophag
import
ensur
therapeut
antibodi
neutral
virus
even
presenc
phagocytosi
minim
risk
ade
phagocytosi
affect
size
immun
aggreg
immun
complex
size
affect
type
fcreceptor
engag
aggreg
refer
selfassoci
number
molecul
form
dimer
oligom
even
submicron
microns
complex
assess
dynam
light
scatter
nanoparticl
track
analysi
antibodi
concentr
affin
stabil
influenc
size
immun
complex
previou
observ
indic
small
immun
complex
colig
activ
increas
antibodi
concentr
result
format
larg
immun
aggreg
colig
lowli
express
inhibitori
receptor
inhibit
phagocytosi
figur
line
observ
morefield
et
al
observ
dendrit
cell
preferenti
phagocytos
smaller
aggreg
compar
aggreg
greater
anoth
studi
fifi
et
al
use
model
polystyren
particl
smaller
particl
um
especi
nm
deliv
effici
dendrit
cell
trigger
product
higher
antibodi
titer
promot
better
type
cell
respons
compar
larger
particl
final
antibodymedi
protect
cryptococcu
neoforman
shown
protect
optim
dose
administr
larg
amount
antibodi
abrog
protect
phagocyt
index
shown
declin
higher
antibodi
concentr
determin
whether
viru
immun
complex
neutral
intracellularli
could
potenti
predict
efficaci
therapeut
antibodi
antibodi
prefer
neutral
viru
infect
level
form
viral
aggreg
would
ensur
viru
neutral
occur
presenc
entri
result
enhanc
antigen
present
activ
adapt
immun
respons
cytokin
product
trigger
activ
signal
event
promot
antivir
respons
activ
dc
lead
increas
antigen
uptak
process
addit
cytokin
allow
recruit
monocyt
dc
site
infect
aid
viru
clearanc
activ
signal
shown
phosphoryl
spleen
tyrosin
kinas
syk
result
upregul
activ
lead
upregul
cytokin
isg
critic
antivir
respons
intermedi
signal
molecul
yet
complet
elucid
other
shown
activ
occur
independ
interferon
signal
signific
immun
shown
knockout
studi
knockout
result
signific
defect
isg
product
dysregul
tcell
macrophag
dc
differenti
result
immun
respons
delay
viral
clearanc
besid
protein
kinas
c
express
activ
shown
import
mhc
class
ii
stimul
present
process
pivot
optim
tcell
activ
strength
natur
immun
respons
trigger
activ
howev
determin
pair
activ
inhibitori
respons
activ
signal
itam
recruit
activ
kinas
trigger
immun
effector
function
contrast
inhibitori
receptor
signal
immunoreceptor
tyrosinebas
inhibitori
motif
itim
activ
phosphatas
inhibit
itam
function
exampl
immun
aggreg
colig
result
recruit
phosphatas
inhibit
phagocytosi
describ
previous
virus
also
colig
inhibitori
receptor
activ
reduc
cytokin
isg
product
inhibitori
receptor
henc
control
rang
cellular
respons
mediat
activ
includ
fceffector
function
phagocytosi
cytokin
product
adcc
cdc
inhibitori
receptor
colig
potenti
reduc
therapeut
efficaci
mab
effect
undesir
instanc
intraven
immunoglobulin
signal
induc
antiinflammatori
respons
potenti
reduc
risk
cytokin
releas
syndrom
mab
therapi
given
import
kinas
phosphatas
mediat
innat
adapt
immun
respons
determin
kinas
phosphatas
profil
cell
mediat
therapeut
antibodi
could
henc
predict
efficaci
antibodi
control
viru
infect
although
kinas
trigger
igg
immun
complex
import
fcmediat
effector
function
overproduct
cytokin
eg
tnfa
due
immun
complex
result
immunogenicityrel
advers
event
instanc
phase
trial
mab
result
immunemedi
cytokin
storm
multiorgan
failur
healthi
volunt
highlight
import
assess
likelihood
advers
event
need
assess
risk
advers
event
even
crucial
engin
antibodi
modifi
fc
region
increas
bind
activ
improv
interact
increas
therapeut
efficaci
antibodi
also
lead
increas
risk
advers
event
henc
cytokin
signatur
encompass
relev
proinflammatori
antiinflammatori
gene
potenti
use
biomark
immun
respons
immun
complex
would
turn
use
predict
clinic
immunogen
risk
therapeut
antibodi
cytokin
signatur
evalu
base
breadth
cytokin
respons
magnitud
respons
number
individu
cytokin
respons
statist
signific
respons
cytokin
signatur
determin
elisa
luminex
cytokin
array
adcc
critic
clearanc
antibodyopson
cell
surfac
receptor
target
surfac
antigen
opson
antibodi
fcreceptor
interact
host
immun
cell
nk
cell
monocyt
macrophag
neutrophil
mast
cell
result
direct
lysi
infect
cell
eventu
lead
viru
clearanc
mani
cell
type
express
activ
inhibitori
may
henc
affect
activ
adcc
among
activ
abund
express
nk
cell
adcc
signal
better
character
rel
activ
import
mediat
adcc
highlight
studi
show
lack
clinic
efficaci
sever
antibodi
eg
infliximab
rituximab
individu
differ
polymorph
observ
correl
vitro
adcc
analysi
peripher
blood
mononuclear
cell
obtain
hh
andor
vv
genotyp
show
higher
adcc
activ
compar
genotyp
lesser
affin
igg
previou
research
also
demonstr
import
adcc
viral
defens
clearanc
instanc
studi
shown
vivo
vitro
import
adcc
control
influenza
rsv
infect
vivo
human
studi
complementmedi
activ
antibodi
hand
caus
direct
cell
lysi
format
membran
attack
complex
mac
process
also
term
cdc
initi
bind
antibodi
complex
result
format
membranebound
convertas
cleav
activ
respect
cleavag
convertas
form
mediat
format
membran
attack
complex
mac
directli
caus
cdc
form
membran
pore
target
cell
simultan
cleavag
result
format
rapidli
degrad
fragment
deposit
fragment
target
cell
bind
express
leukocyt
lead
phagocytosi
adcc
figur
result
neutral
virus
sever
clinic
approv
mab
shown
mediat
function
activ
complement
instanc
antibodi
edrecolomab
antiepitheli
cell
adhes
molecul
mous
mab
alemtuzumab
mab
activ
complement
mediat
adcc
sever
modif
igg
directli
affect
bind
activ
subsequ
cellular
activ
instanc
tripl
mutant
shown
increas
bind
adcc
activ
fc
variant
mutat
design
comput
possess
increas
bind
reduc
bind
result
increas
effector
function
mutat
howev
led
signific
reduct
cdc
antibodi
engin
bear
multipl
substitut
also
show
increas
bind
enhanc
kill
cancer
cell
final
given
critic
role
fclink
glycan
differ
glycan
structur
affect
bind
function
therapeut
antibodi
exampl
afucosyl
antibodi
bind
better
affin
enhanc
abil
mediat
adcc
modifi
antibodi
improv
efficaci
essenti
ensur
caus
immunogen
advers
event
administ
patient
assay
assess
antidrug
antibodi
respons
mainstay
drug
regulatori
author
evalu
therapeut
antibodi
preclin
develop
improv
bind
activ
enhanc
effector
function
fc
modif
could
benefit
patient
polymorph
render
less
respons
therapeut
antibodi
treatment
enhanc
adcc
cdc
effector
function
could
also
engag
immun
system
synergist
manner
potent
viru
neutral
treatment
viral
infect
use
therapeut
antibodi
remain
challeng
task
besid
gener
highaffin
antibodi
virus
therapeut
antibodi
also
trigger
fcmediat
effector
function
facilit
viru
neutral
effector
function
includ
increas
uptak
via
phagocytosi
increas
cytokin
product
lead
enhanc
antigen
present
antivir
respons
increas
adcc
cdc
combinatori
therapeut
strategi
trigger
fcmediat
effector
function
occlud
interact
immun
inhibitori
receptor
could
also
enhanc
clinic
efficaci
therapeut
antibodi
final
virus
infect
replic
within
cell
therapeut
antibodi
mediat
viru
neutral
even
presenc
uptak
thu
mitig
risk
ade
increas
focu
antibodybas
therapeut
burgeon
need
develop
robust
method
rapidli
accur
assess
antibodi
bind
fcreceptormedi
effector
function
routin
test
measur
fcmediat
effect
henc
consid
character
therapeut
antibodi
would
allow
select
develop
therapeut
antibodi
improv
efficaci
reduc
side
effect
addit
antivir
antibodi
respons
polyclon
compris
differ
antibodi
isotyp
effect
therapeut
antibodi
presenc
antibodi
also
test
given
import
interact
antibodymedi
effector
function
fc
modif
could
lead
develop
therapeut
antibodi
improv
interact
activ
could
enhanc
uptak
cytokin
product
antigen
present
adcc
cdc
futur
optim
improv
interact
fcrn
may
also
increas
halflif
therapeut
antibodi
therebi
reduc
risk
ade
associ
use
therapeut
antibodi
virus
infect
cell
grow
number
method
assess
fcmediat
effector
function
technolog
antibodi
modif
believ
therapeut
antibodi
viral
diseas
develop
near
futur
use
diseas
manag
especi
epidem
given
absenc
licens
vaccin
mani
virus
believ
therapeut
antibodi
like
import
treatment
viral
infect
particularli
epidem
specul
futur
advanc
antibodi
engin
result
improv
interact
continu
aid
develop
therapeut
antibodi
possess
improv
clinic
efficaci
better
robust
method
predict
fc
function
fcassoci
effect
clinic
also
continu
essenti
select
therapeut
antibodi
good
efficaci
minim
side
effect
